Ulus Salih Akarca

Ulus Salih Akarca

Auto-generated profile, based on publicly available information

Ulus Salih Akarca

Department of Gastroenterology, Ege University School of Medicine, Izmir, TURKEY

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 March 2014 in Liver International
Verified
Journal Article
Closed access
PDF file
GGGenco Gencdal
Genco Gencdal
FGFulya Gunsar
Fulya Gunsar
CMCenk E. Meral
Cenk E. Meral
ESEsin Salman
Esin Salman
BGBerna Gürsel
Berna Gürsel
UAUlus Salih Akarca
Ulus Salih Akarca

1 February 2010 in European Journal of Gastroenterology & Hepatology
Verified
Journal Article
Closed access
MAMurat Akyildiz
Murat Akyildiz
FGFulya Gunsar
Fulya Gunsar
DNDeniz Nart
Deniz Nart
OSOsman Sahin
Osman Sahin
FYFunda Yılmaz
Funda Yılmaz
UAUlus Akarca
Ulus Akarca
Aim To investigate the macrophage migration inhibitory factor (MIF) expression and −173 G/C polymorphism of the MIF gene in nonalcoholic fatty liver disease (NAFLD). Method Ninety-one patients with diagnosis of NAFLD and 104 healthy controls were included in the study. MIF −173 G/C polymorphism was detected using the PCR–restriction fragment length polymorphism based method. NAFLD was stratified as nonalcoholic steatohepatitis (NASH), probable NASH and steatosis, respectively in groups 1, 2 and 3, according to NAFLD Activity Score. MIF expression was detected by immunohistochemistry staining. Results Mean age of the patients was 50.1±9.6 years, and 54 of them were male. Serum alanine aminotransferase and aspartate aminotransferase were 50/83, 42/63 and 31/32, respectively in groups 1, 2 and 3, (P<0.05). Both the MIF expression of hepatocytes and mononuclear cells were more prominent in groups 1 and 2 than group 3. There was no correlation between MIF expression of hepatocytes and fibrosis stage. However, MIF expression of mononuclear cells significantly increased according to fibrosis stage (P<0.05, R : 0.2). There was no significant correlation between MIF genotype and MIF expression in the liver. Conclusion MIF expression is significantly increased especially by mononuclear cells in liver tissue of patients with NASH secondary to inflammation. Thus, it should be considered as a consequence not a causal factor.

23 September 2022 in Hepatology Forum
Verified
Journal Article
Open access
PDF file
FGFatih Güzelbulut
Fatih Güzelbulut
UKUmit Karaogullarindan
Umit Karaogullarindan
HAHikmet Akkiz
Hikmet Akkiz
EAEngin Altintas
Engin Altintas
CDCoskun Ozer Demirtas
Coskun Ozer Demirtas
RIRamazan Idilman
Ramazan Idilman
Background and Aim: The aim of the present study was to examine the etiology of hepatocellular carcinoma (HCC) by underlying cause and determine the characteristics and clinical features of patients with HCC. Materials and Methods: The study comprised 1802 HCC patients diagnosed and followed up by Liver Diseases Outpatient Clinics in 14 tertiary centers in Turkey between 2001 and 2020. Results: The mean age was 62.3±10.7 years, and 78% of them were males. Of the patients, 82% had cirrhosis. Hepatitis B virus (HBV) infection was the most common etiology (54%), followed by hepatitis C virus (HCV) infection (19%) and nonalcoholic fatty liver disease (NAFLD) (10%). Of the patients, 56% had a single lesion. Macrovascular invasion and extrahepatic spread were present in 15% and 12% of the patients, respectively. The median serum alpha-fetoprotein level was 25.4 ng/mL. In total, 39% of the patients fulfilled the Milan Criteria. When we compared the characteristics of patients diagnosed before and after January 2016, the proportion of NAFLD-related HCC cases increased after 2016, from 6.6% to 13.4%. Conclusion: Chronic HBV and HCV infections remain the main causes of HCC in Turkey. The importance of NAFLD as a cause of HCC is increasing.

24 March 2020 in BMC Health Services Research
Verified
Journal Article
Open access
PDF file
RIRamazan Idilman
Ramazan Idilman
HRHomie Razavi
Homie Razavi
SRSarah Robbins-Scott
Sarah Robbins-Scott
UAUlus Salih Akarca
Ulus Salih Akarca
NÖNecati Örmeci
Necati Örmeci
JLJeffrey Lazarus
Jeffrey Lazarus
Background: In 2016, WHO passed the Global Health Sector Strategy on Viral Hepatitis (GHSS), calling for its elimination by 2030. Two years later, Turkey approved a strategy to reach the WHO targets. This study reports new national prevalence data, breaks it down by subpopulation, and models scenarios to reach HCV elimination.Methods: Literature was reviewed for estimates of HCV disease burden in Turkey. They were discussed with stakeholders and used as inputs to develop a disease burden model. The infected population was estimated by sequelae for the years 2015–2030. Three scenarios were developed to evaluate the disease burden in Turkey: a Base 2017 scenario, representing the current standard of care in Turkey; an increased treatment scenario, representing the impact of improved access to DAAs; and a WHO targets scenario, which meet the WHO GHSS viral hepatitis targets of a 65% reduction in mortality and 90% diagnosis rate of the infected population by 2030.Results: At the beginning of 2017, 271,000 viremic infections were estimated. Of these, 58,400 were diagnosed and 10,200 treated. Modelling results showed that, with the current treatment paradigm in Turkey, by 2030 the total number of viremic HCV infections would decline by 35%, while liver-related deaths, hepatocellular carcinoma (HCC), and decompensated cirrhosis would decrease by 10–25%. In theincreased treatment scenario, by 2030 viremic HCV infections would decrease by 50%; liver-related deaths, HCC and decompensated cirrhosis would decrease by 45–70%. In theWHO targets scenario, HCV infections would decrease by 80%; sequelae would decrease by 80–85%. Data on disease burden in micro-elimination target subpopulations are largely unavailable.Conclusions: To meet the WHO Global Health Sector Strategy targets for the elimination of HCV, Turkey needs to increase treatment. Better data are needed as well as countrywide access to DAAs.

30 November 2021 in Turkish Journal of Gastroenterology
Verified
Journal Article
Open access
UAUlus Salih Akarca
Ulus Salih Akarca
BUBelkis Unsal
Belkis Unsal
OSOrhan Sezgin
Orhan Sezgin
KYKendal Yalcin
Kendal Yalcin
MAMeral Akdogan
Meral Akdogan
OGon behalf of 3K Registry Study Group
on behalf of 3K Registry Study Group
Hepatocellular carcinoma,epidemiology,risk factors,prognostic factors,screening,Turkey

15 November 2018 in Turkish Journal of Gastroenterology
Verified
Journal Article
Closed access
MZMurat Zeytunlu
Murat Zeytunlu
AUAlper Uguz
Alper Uguz
ÖÜÖmer Ünalp
Ömer Ünalp
OEOrkan Ergün
Orkan Ergün
ZKZeki Karasu
Zeki Karasu
NANurşen Altuğ
Nurşen Altuğ
Background/Aims: Liver transplantation (LT) is now the standard of care for most end-stage liver diseases. Over the next 30 years, advances in medicine and technology will greatly improve the survival rates of patients after this procedure. The aim of the present study was to analyze retrospectively the results of 1001 patients withLT. Materials and Methods: Medical reports of 989 patients were analyzed retrospectively. Data were obtained from the patient’s data chart. Descriptive statistics were used to describe continuous variables (mean, median, and standard deviation). Results: A total of 1001 LTs for 989 recipients were performed at Ege University Organ Transplantation and Research Center between 1994 and 2017. Therewere 639 male and 350 female recipients. Among 1001 LTs, there were 438 deceased donors and 563 living donors. The age interval of the patients was 4 months to 71 years old. The median Model for End-Stage Liver Disease score was 20. There were 12 deceased liver donors using the split method. There were 12 cases subject to retransplantation. In living donor LT grafts, 423 right lobes, 46 left lobes, and 94 left lateral sectors were used. In the first monitoring,the total annual mortality rate was 130 cases (13%). The mortality rate in retransplantation was found to be 66%. A 1-year survival rate of 87% was generally established. Conclusion: LThas been improving consistently over the last two decades. Ege University is one of the biggest liver transplant centers in Turkey for both technical and educational perspective. Cite this article as: Zeytunlu M, Uğuz A, Ünalp Ö, et al. Results of 1001 liver transplantations in 23 years: Ege University experience. Turk J Gastroenterol 2018; 29: 664-8.